Henry E. Huntington in 1907.; Credit: Theo C. Marceau, New York City. The Huntington Library, Art Museum, and Botanical Gardens

One of the most prized treasures of LA County is 100 years old this year.

The Huntington Library is beloved for its lush botanical gardens and fine art.

As KPCC's Brianna Flores reports, you can trace its origins to a pivotal moment in Southern California history.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Opera singer Plácido Domingo, shown here speaking in Spain last July, said earlier this month that he tested positive for the coronavirus.; Credit: Ricardo Rubio/Europa Press via Getty Images

Plácido Domingo has been hospitalized because of COVID-19-related complications, according to multiple reports.

He is in stable condition in an Acapulco, Mexico, hospital and will receive medical attention for "as long as the doctors find it necessary until a hoped-for full recovery," a spokesperson for Domingo told Opera News over the weekend.

Domingo's reported hospitalization comes just days after he posted a March 22 message on Facebook revealing that he had tested positive for the disease caused by the coronavirus.

"I feel it is my moral duty to announce that I tested positive for COVID19, also known as the Corona Virus. My family and I are and will remain individually isolated for as long as it is medically necessary. Today we all enjoyed good health, but I presented symptoms of coughing and fever, so I decided to take the test and the result was positive," Domingo said.

Domingo has been one of opera's most reliable and bankable stars and is known for his ability to sing tenor and baritone and in multiple languages, including Italian, English, Russian and Spanish.

Recently, the 79-year-old has been embroiled in controversy as several women accused the Spanish-born singer of sexual misconduct.

On March 10, NPR reported that LA Opera, which Domingo helped establish, announced that its investigation substantiated 10 "inappropriate conduct" claims levied against him dating back to as early as 1986. Domingo resigned as the LA Opera's general director in October.

Prior to that, he withdrew from a production of the Metropolitan Opera's performance of "Macbeth" amid allegations of sexual misconduct.

He has denied the allegations.

Domingo is among a growing list of celebrities who have announced they have tested positive for the coronavirus, including actor Tom Hanks and his wife Rita Wilson, actor Idris Elba, NBA star Kevin Durant, talk show host Andy Cohen and British Prime Minister Boris Johnson.

This content is from Southern California Public Radio. View the original story at SCPR.org.

After the San Francisco 49ers beat the Atlanta Falcons for the right to go to the Super Bowl, I tweeted my appreciation of a California team going to the game.  If no local team is in the running (or exists), I'm always glad to root for a Bay Area team that makes it.

My tweet got responses from some Southern Californians who have no interest in supporting a San Francisco team, especially given the Giants' World Series championship.  It goes without saying that many Dodger fans are loathe to support the Giants, under any circumstances. 

Given the historic bad blood between the teams, that's no surprise, but I think it runs even deeper.  The divide between Northern and Southern California is about more than sports, or even water rights.  It's rooted in distinct cultural differences between the two.

However, California has evolved to the point where the bigger cultural divide now might be between coastal and inland regions.  Rural Northern Californians typically dislike San Francisco far more than Angelenos do.  Similarly, inland Southern California residents often see Los Angeles as the prohibitively expensive home of two-hour traffic jams.

Until the Inland Empire or the San Joaquin Valley get major league teams, we won't see that rivalry playing out at a stadium near you.   In the meantime, I'm cheering on the Niners, and my state, on February 3rd.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Updated at 10 p.m. ET

Australia's High Court has found reasonable doubt that Cardinal George Pell sexually assaulted two boys in the 1990s and has overturned his conviction.

The court acquitted the former Vatican treasurer of the charges, and no retrial will be possible.

Pell, 78, had been serving a six-year prison sentence in the case. The High Court ordered that he be released.

He was convicted of sexually abusing two 13-year-old choirboys at St. Patrick's Cathedral in Melbourne.

As an adult, one of them went to the police in 2015 and accused the cardinal of abusing him and the other boy in 1996. The other individual died of a heroin overdose the previous year without reporting abuse.

In a statement after the acquittal, as reported by Reuters, Pell said, "I hold no ill will toward my accuser, I do not want my acquittal to add to the hurt and bitterness so many feel; there is certainly hurt and bitterness enough."

Pell was convicted in 2018 and an appellate court upheld those convictions last year.

The Australian Catholic Bishops Conference's comments on the acquittal recognize that the outcome will be good news for some people and "devastating for others."

"The result today does not change the Church's unwavering commitment to child safety and to a just and compassionate response to survivors and victims of child sexual abuse. The safety of children remains supremely important not only for the bishops, but for the entire Catholic community. Any person with allegations of sexual abuse by Church personnel should go to the police."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Supreme Court Justice Ruth Bader Ginsburg poses for the official photo at the Supreme Court in Washington, D.C. in 2018.; Credit: Mandel Ngan/AFP via Getty Images

Supreme Court Justice Ruth Bader Ginsburg underwent non-surgical treatment Tuesday for a benign gallbladder condition, according to a press release from the Supreme Court. She plans to participate in oral arguments from the hospital on Wednesday, according to the release.

In pain on Monday, Ginsburg went to Sibley Memorial Hospital in Washington after hearing the first-ever Supreme Court teleconference of oral arguments. At Sibley, she was diagnosed with acute cholecystitis, a condition in which a gallstone migrates to the cystic duct. She nonetheless participated in arguments from home on Tuesday, but was in enough pain that she went to Johns Hopkins Hospital in Baltimore for treatment of the infected duct later Tuesday.

Doctors not involved in Ginsburg's care said non-surgical treatment typically involves antibiotics and insertion of a tube to drain the infected duct.

Friends said the justice was in good spirits on Tuesday night, and watching the Metropolitan Opera on her iPad.

Ginsburg's emergency treatment coincides with the U.S. Supreme Court's historic live-streaming of its oral arguments in which the justices are participating by telephone because of the coronavirus. According to the court statement, Ginsburg, 87, is "resting comfortably" and plans to participate in oral arguments again on Wednesday when the court considers an important birth control case.

She is expected to remain in the hospital for another day or two.

Last year, Ginsburg completed three weeks of radiation treatment after a cancerous tumor was discovered on her pancreas. It was the fourth time in 20 years that she had been treated for cancer, and the second time in a year. In December 2019, she was operated on for lung cancer.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Julio Osorio stands in the Valhalla Memorial Park Cemetery near his mother's grave. (Emily Elena Dugdale/KPCC); Credit: Emily Elena Dugdale

The devastating Woolsey fire broke out one year ago. In Malibu, it wreaked havoc not only on hundreds of homeowners but also on the day laborers, housekeepers and gardeners who traveled to the city to work in its affluent neighborhoods.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: Illustration: Dan Carino

Read the full article at LAist

Coronavirus deaths in the U.K. have passed those in Italy. Workers in the intensive care unit at the Royal Papworth Hospital in Cambridge are shown gearing up to care for COVID-19 patients.; Credit: Neil Hall/AP

Over 32,000 people have died from the new coronavirus in the United Kingdom, according to the Office for National Statistics, marking the first time in the pandemic that it has led Europe in the number of deaths.

The country has surpassed Italy in COVID-19 deaths. The U.S. still leads the world in the highest number of coronavirus deaths; over 70,270 had died from the disease as of Tuesday.

The number of total deaths recorded in the U.K. is "higher than we would wish, I think is all I can say," Angela McLean, chief scientific adviser of Ministry of Defence said during the country's press briefing Tuesday.

McLean also emphasized that deaths in U.K. care homes have been steadily rising and said the trend was something the country "need[s] to get to grips with."

"I don't think we'll get a real verdict on how well countries have done until the pandemic is over," British Foreign Secretary Dominic Raab said Tuesday. "And particularly until we have comprehensive international data on all causes of mortality."

Since different countries collect and report coronavirus data using different methods, the comparisons between regions are not perfect. As more time passes and more tests are conducted and more data comes in, coronavirus death rates will become more precise.

The peak in deaths comes as other European countries, including Italy and Spain, are easing shelter-in-place restrictions, while U.K. Prime Minister Boris Johnson is expected to modify Britain's orders in the next week.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Robert F. Kennedy's speech at the Ambassador Hotel. Sandi Gibbons the woman in the white dress on the bottom right.

She’s spent her life on both sides of the microphone.

For half of her career she was a reporter, finding herself in places like the Ambassador Hotel ballroom on the night Robert F. Kennedy was shot, and in the courthouse covering Charles Manson.

For the other half of her professional life, she spent a lot more time in L.A.’s courthouses as the spokeswoman for the L.A. County District Attorney’s office. She served three DAs, and now she’s hanging it up. Her retirement lunch was attended by three past and present DAs, with a fond message from a fourth, and as many of her reporter and DA friends could fit in the restaurant.

RELATED: Veteran reporter, DA spokesperson Sandi Gibbons is retiring

Sandi Gibbons has tales to tell, and here she recounts a few funny, moving and plain old perplexing ones from her life in court. And I can tell you from knowing her, she is one great dame.

Correction: Original headline spelled Sandi Gibbons' name "Sandy"

This content is from Southern California Public Radio. View the original story at SCPR.org.

Jiro's Pick this week is joyPlot by Santiago Benito.I must admit that I was simply drawn by the visualization, rather than the name of the function, as I was not familiar with the band or the music... read more >>

'California Mountain Lions,' Episode 7: Human Interaction

An image released by Google shows an early version of its driverless vehicle. The company has built several prototypes of the self-driving car.; Credit: /Google

California is one step closer this week to making the 1980s Hollywood fantasy of Knight Rider a 21st century reality because permits for self-driving cars issued by the Department of Motor Vehicles officially went into effect Tuesday. Now a handful of companies can test automated cars on public roads.

Buckle up — it's gonna be a wild ride.

John O'Dell is a Senior Editor at Edmunds.com, and he joins Alex Cohen to talk about what this means for the future of the driverless car industry.

 

In this file photo, job seekers line up to enter Choice Career Fair at the Los Angeles Convention Center on December 1, 2010 in Los Angeles, California. Overall, the number of unemployed Californians ticked up by 1,000 over the month to nearly 1.4 million for August 2014, but the rate remained unchanged, at 7.4 percent. The national unemployment rate is down to 6.1 percent.; Credit: Kevork Djansezian/Getty Images

California's unemployment rate is unchanged for a third month, holding at 7.4 percent in August.

The California Employment Development Department reported Friday that the state added 44,200 nonfarm jobs during the month, bringing the state total to 15.5 million in August.

Last month's gains mean the state has added 1.4 million jobs since February 2010, when the jobless number hit a peak of 12.4 percent.

Overall, the number of unemployed Californians ticked up by 1,000 over the month to nearly 1.4 million. The national unemployment rate is down to 6.1 percent.

Construction posted the largest increase over the month, adding 13,600 jobs. Manufacturing, financial activities, business services, education, health, leisure and government all added jobs in August.

Trade, transportation and utilities, along with information, posted job losses of 8,300.

Founder and Executive Chairman of Alibaba Group Jack Ma (L) attends the company's initial price offering (IPO) at the New York Stock Exchange on September 19, 2014 in New York City. ; Credit: Andrew Burton/Getty Images

Alibaba's stock is surging as the Chinese e-commerce powerhouse begins its first day trading as a public company.

The stock opened at $92.70 and nearly hit $100 on the New York Stock Exchange Friday, a gain of 46 percent from the initial $68 per share price set Thursday evening.

At Friday's opening price, the company is worth $228.5 billion, more than companies such as Amazon, Ebay and even Facebook.

Jubilant CEO Jack Ma stood on the NYSE trading floor Friday as eight Alibaba customers, including an American cherry farmer and a Chinese Olympian, rang the opening bell.

"We want to be bigger than Wal-Mart," Ma told CNBC shortly after the opening Bell. "We hope in 15 years people say this is a company like Microsoft, IBM, Wal-Mart, they changed, shaped the world."

On Thursday, Alibaba and the investment bankers arranging the initial public offering settled on a price of $68 per share. The company and its early investors raised $21.8 billion in the offering, which valued Alibaba at $168 billion in one of the world's biggest ever initial public offerings.

The company, which is trading under the symbol "BABA," has enjoyed a surge in U.S. popularity over the past two weeks as investors met with executives, including its colorful founder Jack Ma. As part of the so-called roadshow, would-be investors heard a sales pitch that centered on Alibaba's strong revenue growth and seemingly endless possibilities for expansion. Demand was so high that the company raised its offering price to $66 to $68 per share from $60 to $66 per share on Monday.

The main reason investors appear breathless about the 15-year old Alibaba: It offers an investment vehicle that taps into China's burgeoning middle-class.

Alibaba's Taobao, TMall and other platforms account for some 80 percent of Chinese online commerce. Most of Alibaba's 279 million active buyers visit the sites at least once a month on smartphones and other mobile devices, making the company attractive to investors as computing shifts away from laptop and desktop machines.

And the growth rate is not expected to mature anytime soon. Online spending by Chinese shoppers is forecast to triple from its 2011 size by 2015. Beyond that, Alibaba has said it plans to expand into emerging markets and eventually, Europe and the U.S.

"There are very few companies that are this big, grow this fast, and are this profitable," said Wedbush analyst Gil Luria.

Alibaba operates an online ecosystem that lets individuals and small businesses buy and sell. It doesn't directly sell anything, compete with its merchants, or hold inventory.

"The business model is really interesting. It's not just an eBay, it's not an Amazon, it's not a Paypal. It's all of that and much more," said Reena Aggarwal, a professor at Georgetown.

Like China's consumer and Internet market, Alibaba is still growing rapidly. The company's revenue in its latest quarter ending in June surged 46 percent from last year to $2.54 billion while its earnings climbed 60 percent to nearly $1.2 billion, after subtracting a one-time gain and certain other items.

In its last fiscal year ending March 31, Alibaba earned $3.7 billion, making it more profitable than eBay Inc. and Amazon.com Inc. combined. Amazon ended Thursday with a market value of about $150 billion while eBay's market value stood at $67 billion.

Alibaba, is based in Hangzhou in Eastern China, Ma's hometown. The company got started in 1999 when Ma and 17 friends developed a fledgling e-commerce company on the cusp of the Internet boom. Today, Alibaba's main platforms are its original business-to-business service Alibaba.com, consumer-to-consumer site Taobao and TMall, a place for brands to sell to consumers.

And while there's plenty of growth left in China, Ma has recently hinted about plans to expand beyond those borders.

"We hope to become a global company, so after we go public in the U.S., we will expand strongly in Europe and America," Ma said to a group of reporters in Kowloon on Monday.

Alibaba offered 320.1 million shares for a total offering size of $21.77 billion. Underwriters have a 30-day option to buy up to about 48 million more shares. That means the offering size could be as much as $25 billion

The IPO's fundraising handily eclipses the $16 billion Facebook raised in 2012, the most for a technology IPO. If all of its underwriters' options are exercised, it would also top the all-time IPO fundraising record of $22.1 billion set by the Agricultural Bank of China Ltd. in 2010.

Yahoo, which has been struggling to grow for years, made a windfall $8.28 billion by selling 121.7 million of is Alibaba shares. And founder Jack Ma sold 12.75 million shares worth $867 million.

A job seeker fills out an application during a career fair at the Southeast Community Facility Commission on May 21, 2014 in San Francisco; Credit: Justin Sullivan/Getty Images

California employers added 44,200 jobs in August, the largest gain of any state in the country. The state's unemployment rate stood still at 7.4 percent, compared to 6.1 percent nationwide.

"When the national numbers came out for August, and we saw a significant slowdown in job creation, we were a little bit concerned that we'd see the same thing happening here," said economist Kimberly Ritter-Martinez of the Los Angeles County Economic Development Corporation. "But in California, we stayed pretty much on track, outpacing the nation in terms of job creation." 

The construction sector was a huge contributor to California's job growth in August, with a gain of 13,600 jobs.  The other sectors with large gains were Education/Health Services (+12,200), and Professional/Business Services (+10,600). 

"We've been seeing steady increases in construction employment for some time, but it has been a slow steady increase," said Tom Holsman, CEO of the Associated General Contractors of California.

"Recent increases are attributable to many projects that have been in the early stages of startup gaining momentum," Holsman added, citing LA County Metro transit projects and the new Wilshire Grand Hotel construction project as local examples.

In Los Angeles County, the unemployment rate also stayed flat at 8.1 percent, but it remains far lower than the 9.9 percent of August of 2013. In the last twelve months, the L.A. County Metro area has gained 6,600 construction jobs, a rate of 5.6 percent.

Ritter-Martinez, of the LAEDC says other economic indicators support a boost in construction jobs at the Los Angeles and statewide levels: permits for new housing construction, remodeling, and non-residential construction are all on the rise. 

"Builders and developers are reporting that they're having trouble finding some skilled labor for construction," Ritter-Martinez said. "It's taken so long for that sector to come back, a lot of construction people have gone off and found other kinds of jobs or moved out of the region." 

In Orange County, the unemployment rate was 5.4 percent, down from 5.7 percent in July. The unemployment rate in the Riverside-San Bernardino-Ontario area was 8.7 percent in 
August 2014, down from a revised 9.3 percent in July 2014.

US-based fintech Namogoo will integrate incentive platform

Source: Streetwise Reports   04/29/2020

Biopharmaceutical company Chimerix Inc. (CMRX:NASDAQ), which focuses on developing medicines to treat cancer and other serious diseases, today announced that it will initiate a Phase 2/3 study of dociparstat sodium (DSTAT) in COVID-19 patients suffering from acute lung injury (ALI).

The firm explained that "DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties, including the potential to address underlying causes of coagulation disorders with substantially reduced risk of bleeding complications compared to commercially available forms of heparin.^"

Joseph Lasky, M.D., Professor of Medicine, Pulmonary and Critical Care Section Chief, John W. Deming, M.D. Endowed Chair in Internal Medicine at Tulane University Medical School commented, "Given the severity of the COVID-19 pandemic, we have evaluated many potential targets to address the clinical manifestations associated with severe COVID-19...Based on the literature, we believe DSTAT has the potential to reduce the excessive inflammation, immune cell infiltration and hypercoagulation associated with poor outcomes in patients with severe COVID-19 infection."

The company's CEO Mike Sherman remarked, " DSTAT is well-suited to unlock the anti-inflammatory properties of heparin as it may be dosed at much higher levels than any available form of heparin without triggering bleeding complications...We had planned to evaluate DSTAT in several indications of high unmet need, including ALI from different causes. The pandemic intensified our focus on ALI associated with COVID-19. Our team has worked closely with critical care physicians treating COVID-19 patients and with the U.S. Food and Drug Administration (FDA) to develop a Phase 2/3 protocol to determine if DSTAT can reduce the need for mechanical ventilation and improve the rate of survival in patients with severe COVID-19 infection."

The company outlined its plans for the study indicating that it will be a randomized, double-blind Phase 2/3 trial to determine the safety and efficacy of DSTAT in adults with severe COVID-19 who are at a high risk of respiratory failure. The study subjects will be confirmed COVID-19 patients who require hospitalization and supplemental oxygen therapy. The primary endpoint established in the study is the percentage of subjects who survive and do not require mechanical ventilation through 28 days. Several secondary endpoints listed include time needed for showing improvement, time to hospital discharge, time to resolution of fever, number of ventilator-free days, all-cause mortality and changes in several key biomarkers.

The study will begin by enrolling 24 subjects in Phase 2 to first establish dosage levels and then expand to 74 total patients. The firm advised that if Phase 2 results are positive, it would enroll approximately 450 subjects in the Phase 3 portion of the study.

The company reported that "the clinical manifestations of COVID-19 range from mild, self-limited respiratory tract illness to severe alveolar damage and progressive respiratory failure, multiple organ failure, and death. Mortality in COVID-19 is associated with severe pulmonary disease and coagulation disorders such as disseminated intravascular coagulation." The firm indicated that the mechanisms of action of DSTAT may address overactive inflammatory response including underlying causes of blood coagulation disorders associated with COVID-19.

Chimerix is a development-stage biopharmaceutical company based in Durham, N.C. which is engaged in advancing medicines in the areas of cancer and other serious diseases. The company listed that it presently has two active clinical-stage development programs. The first is dociparstat sodium (DSTAT) which is a glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity. The second pipeline candidate is brincidofovir (BCV) which is an antiviral drug being developed as a medical countermeasure for smallpox.

Chimerix began the day with a market capitalization of around $93.2 million with approximately 61.74 million shares outstanding. CMRX shares opened 30% higher today at $1.97 (+$0.46, +30.46%) over yesterday's $1.51 closing price. The stock has traded today between $1.82 to $2.62 per share and is currently trading at $2.27 (+$0.76, +50.33%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: CMRX:NASDAQ, )

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: The Vitamin D potential for reducing risk of coronavirus Ted Cruz continues to impress and entertain General Flynn coverage contrast, FOX versus CNN Nate Silver’s coronavirus analysis insights Press Secretary Kayleigh McEnany’s zingers If you would like to enjoy this same content plus bonus content […]

The post Episode 963 Scott Adams: Reviewing the Two Movies of Reality and the New Press Secretary’s First Days appeared first on Scott Adams' Blog.

Scientists involved in a pan-European project to develop better methods of risk assessment say maps that show such cumulative risks geographically are easy to interpret and should be considered as practical tools for conveying risk information to decision makers and the general public.

Global air quality will significantly deteriorate by 2050 unless further steps are taken to cut current emissions from human activities, according to recent research. Most people around the world will be affected by worsening air quality with hotspots of particularly poor air occurring in China, northern India and the Middle East.

Neither the public nor conservation managers are fully aware of the different risks posed by invasive alien species (IAS), new research suggests. A study examining perceptions of five invasive species in the UK shows that both conservation managers and the public regard some highly damaging species as ???low risk???, and that their awareness does not increase with the amount of scientific research on the topic.

Invasions of alien species are rising at an alarming rate, largely due to growing global trade and transport routes. Preventing the successful establishment of alien species by better understanding the factors determining success is a step toward limiting the threat of future biological invasions. Statistical modelling using observed bird invasion data — including location, event and species-level factors showed which factors were key to successful establishment by the alien species.

A survey of over 600 private boats docked in marinas throughout the Mediterranean showed that 71% are carrying non-indigenous species. In certain cases, non-indigenous species can become ‘invasive’ and have enormous and long-lasting impacts on ecosystems. The findings suggest that a common monitoring strategy may be necessary to prevent further disruptions to natural ecosystems.

New research has produced a starch-based bioplastic with similar properties to equivalent traditional oil-based plastics. By adding an ammonium salt to thermoplastic starch (TPS) the study demonstrated an improvement in the plasticisation process, rendering it flexible, mouldable and potentially recyclable.

Staff in buildings that have been certified as ‘green’ under the LEED scheme are just as satisfied with their indoor working environment as people working in non-LEED buildings, according to research on commercial buildings. The study suggests that investment in the thermal and acoustic aspects of buildings, however, would further improve occupant satisfaction.

A new tool to help environmental managers make faster, more evidence-based decisions on how to eradicate alien aquatic species has been developed. The tool is a statistical model based on over 140 management case studies in the scientific literature. Packaged as a user-friendly computer program, it allows different management options to be easily compared.

The impact of air quality on public welfare is important to policy development. However, it is difficult to make a clear link between the two when air pollution tends to be reported at a country level and wellbeing is an individual measure. A new study takes a step further towards linking the two by analysing regional level air quality across the EU and relating it to levels of life satisfaction.

Harbour sediments should be tested for their toxic effects on living organisms in addition to being subject to the chemical, physical and biological tests usually conducted to assess water quality, according to recent research from Portugal. This would provide a better environmental assessment of dredged material to help guide port authorities’ decisions on its disposa

Sea level rise may cause soils in coastal regions to become more saline. In a recent study, reproduction in soil invertebrates was impaired in soils containing salt levels below the threshold used currently to define saline soils. The authors recommend community-level studies to further investigate the salt concentrations that are harmful to soil organisms.

Alien plant invasions can have significant environmental, ecosystem and economic implications. Since ornamental horticulture is the primary pathway for invasive alien plant introductions, it is a suitable focus for prevention policies. A recent review of published evidence has examined the effectiveness of four major instruments: pre-border import restrictions, post-border sales bans, industry codes of conduct, and consumer education. The study highlights that, while each instrument has the potential to contribute to a reduction in plant invasion risk, none is sufficient to achieve this goal alone. The researchers, therefore, describe how the four instruments can be integrated along the ornamental horticulture industry supply chain to reduce risk more effectively, and outlines the role that government, industry and other stakeholders must play to achieve this goal.

The fossil remains of a new tiny species of marsupial lion which prowled the lush rainforests of northern Australia about 18 million years ago have been unearthed in the Riversleigh World Heritage Area of remote north-western Queensland.

read more

Effective flood-risk management requires accurate risk-analysis models. Conventional analysis approaches, however, are based on the evaluation of spatially homogenous scenarios, which do not account for variation in flooding across a river reach/ region. Since flood events are often spatially heterogeneous (i.e. unevenly distributed), this paves the way for error. Now, scientists have developed a novel framework for risk analysis that accounts for their heterogeneity, and successfully demonstrated the accuracy of the approach by applying it in a proof-of-concept exercise in Vorarlberg, Austria. By facilitating improved prediction and quantification of flood events, this model is likely to inform future flood-risk management and related decision-making.

A new Cochrane Review, published in the Cochrane Library today and presented at the ERS International Congress, has found evidence from randomised trials, that taking an oral vitamin D supplement in addition to standard asthma medication is likely to reduce severe asthma attacks.

read more

Recent research in Italy has suggested that soil quality deteriorates over time when intensively farmed under plastic tunnels. The tunnels are an obstacle to natural rainfall and artificial irrigation increases soil salinity and, as a consequence, agricultural yields can be significantly reduced.

Although soil quality is best assessed using a wide range of indicators, a smaller set may be more practical and still provide the necessary information needed to choose between land management systems. This is the conclusion of a new study in Brazil that evaluated three different indexes of soil quality based on three sets of indicators.

Restoration of upland bog habitats by blocking drainage channels has caused concern among some sheep farmers that this will reduce the quality of grazing areas. However, UK researchers have shown that drainage does not encourage growth of plants favoured by sheep, nor do sheep use drained areas more. Therefore they conclude such restoration measures are unlikely to detrimentally affect sheep grazing.

Adding compost, manure, and other forms of organic matter to farmland soil can boost earthworm numbers, crop yield, and the stability of soil, finds a recent analysis of long-term case studies. No-tillage and crop-rotation practices also have positive effects on soil, although no-tillage's benefits for earthworms are often absent on farms that use herbicides and other pesticides. The study also confirms that organic farming typically produces lower crop yields than conventional farming, but provides recommendations on how to reduce this ‘yield gap’, while highlighting positive aspects of organic agriculture.

The number and impacts of disasters have increased in Europe in the period 1998-2009, a new report by the European Environment Agency (EEA) concludes. The report assesses the frequency of disasters and their impacts on humans, the economy and ecosystems and calls for better integrated risk management across Europe.

Scientists involved in a pan-European project to develop better methods of risk assessment say maps that show such cumulative risks geographically are easy to interpret and should be considered as practical tools for conveying risk information to decision makers and the general public.

The impact of air quality on public welfare is important to policy development. However, it is difficult to make a clear link between the two when air pollution tends to be reported at a country level and wellbeing is an individual measure. A new study takes a step further towards linking the two by analysing regional level air quality across the EU and relating it to levels of life satisfaction.

Nanomaterials – at a scale of one thousand times smaller than a millimetre – offer the promise of radical technological development. Many of these will improve our quality of life, and develop our economies, but all will be measured against the overarching principle that we do not make some error, and harm ourselves and our environment by exposure to new forms of hazard. This Thematic Issue explores recent developments in nanomaterials research, and possibilities for safe, practical and resource-efficient applications.